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ABSTRACT
Objective: Vancomycin resistant enterococci (VRE) are important healthcare associated multidrug resistant organisms 
because of their easily spread in the hospital environment, difficulty to cure and high mortality rate. The aim of this 
study was to evaluate in vitro activity of daptomycin and tigecycline against VRE strains isolated from rectal swab 
samples of hospitalized patients.  
Methods: Sixty non-duplicate VRE strains isolated from rectal swabs of hospitalized patients between October 2010 
and February 2013 at Ankara Training and Research Hospital were included into the study. Ankara Training and Research 
Hospital in Ankara in Turkey is a 600-bed, tertiary care, teaching hospital. Minimum inhibitory concentration (MIC) val-
ues of daptomycin and tigecycline were determined by E-test method (bioMerieux, France).
Results: All of the strains were susceptible to daptomycin, three of them (5%) were resistant to tigecycline. MIC50 and 
MIC90 values of daptomycin were 1.5 µg/ml and 2 µgr/ml, and of tigecycline were 0.64 µg/ml and 0.125 µg/ml, respec-
tively.
Conclusion: As a result; all of the strains were susceptible to daptomycin. On the other hand, resistance to tigecycline 
was exhibited by 5% of VRE isolates. Clinicians should be aware of the possibility of the emergence of tigecycline non-
susceptibility and should closely monitor tigecycline MICs of enterococci. J Microbiol Infect Dis 2014; 4(3): 107-110
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Rektal sürüntü kültürlerinden izole edilen vankomisin dirençli enterokok suşlarının 
daptomisin ve tigesiklin duyarlılıkları
ÖZET
Amaç: Hastane ortamında kolay yayılımı, infeksiyonlarının tedavisinin zor ve mortalite oranlarının yüksek olması ne-
deni ile çoklu ilaca dirençli vankomisin dirençli enterokoklar (VRE) önemli organizmalardır.  Bu çalışmanın amacı; yatan 
hastalardan alınan rektal sürüntü örneklerinden izole edilen VRE suşlarında in vitro daptomisin ve tigesiklin duyarlılığını 
belirlemektir.
Yöntemler: Çalışmaya Ekim 2010- Şubat 2013 tarihleri arasında Ankara Eğitim ve Araştırma Hastanesinde yatan has-
taların rektal sürüntülerinden izole edilen 60 VRE suşu dahil edildi. Ankara Eğitim ve Araştırma hastanesi 600 yataklı 3. 
basamak bir araştırma hastanesidir. Daptomisin ve tigesiklin için minimum inhibitor konsantrasyon (MIK) değerleri E-test 
yöntemi (bioMerieux, Fransa) ile belirlendi.
Bulgular: Tüm suşlar daptomisine duyarlı olup; üçü (%5) tigesikline dirençli saptandı. Daptomisin için MIK50 ve MIK90 
değerleri sırasıyla 1.5 µgr/ml ve 2 µgr/ml saptanırken tigesiklin için 0.064 µg/ml ve 0.125 µg/ml olarak saptandı. 
Sonuç: Sonuç olarak; tüm suşlar daptomisine duyarlı saptandı. Diğer yandan VRE izolatlarında tigesiklin direnci %5 
olarak saptandı. Klinisyenler enterokoklarda tigesiklin direncine karşı dikkatli olmalı ve tigesiklin MIK değerini yakından 
takip etmelidir.
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INTRODUCTION
Antimicrobial drug resistance is a growing public 
health problem, and multidrug-resistant pathogens 
such as vancomycin resistant enterococci (VRE) 
are increasing worldwide, with the increased con-
sumption of glycopeptides. The limited therapeutic 
options currently available for the treatment of VRE 
infections emphasize the need for new antimicrobial 
agents with activity against these pathogens and for 
ongoing efforts to limit the transmission of VRE in 
health care settings.1,2 The clinical importance of the 
genus Enterococcus is directly related to its antibi-
otic resistance, which contributes to the risk of colo-
nization and infection.3 However, colonizations are 
far more frequent than infections.4 Daptomycin and 
tigecycline are effective in the treatment of infec-
tions related to gram positive bacteria.5,6 Daptomy-
cin, a cyclic lipopeptide produced by Streptomyces 
roseosporus, approved for the treatment of compli-
cated skin and soft-tissue infections and Staphylo-
coccus aureus bloodstream infection, is the only an-
tibiotic with in vitro bactericidal activity against VRE 
that is approved by the Food and Drug Administra-
tion (FDA).7 Daptomycin exhibits a lower potency 
against enterococci than staphylococci.8,9  Tigecy-
cline, the first member of a new class of broad-spec-
trum antibiotics, the glycylcyclines was licensed for 
the parenteral treatment of adult patients with com-
plicated intra-abdominal infections and complicated 
skin and soft tissue infections.10 Tigecycline is highly 
active against Gram-positive pathogens, including 
methicillin resistant S. aureus (MRSA), methicillin 
resistant S. epidermidis (MRSE) and vancomycin 
susceptible and resistant enterococci.11,12 The aim 
of this study was to evaluate the in vitro activity of 
daptomycin and tigecycline against VRE isolates.
METHODS
This study performed at a 600 bed tertiary care 
hospital which has an infection control commitee. 
In the period from October 2010 to February 2013, 
60 non-duplicated vancomycin resistant Entero-
coccus faecalis and Enterococcus faecium strains 
were isolated from rectal swab cultures from pa-
tients  intensive care units and various clinics  in our 
hospital. The isolates were stored at -20°C in brain 
heart infusion broth, suplemented with glycerol, be-
fore testing. The isolates were grown overnight on 
sheep blood agar at 37°C for 24 h and were tested 
for ampicillin, erithromycin, vancomycin, teicoplanin 
and linezolid. Suspension of the isolates in 0.5 Mc-
Farland was prepared and inoculated on to Muel-
ler Hinton agar plates. The testing of the antimicro-
bial susceptibilities to the ampicillin, erythromycin, 
vancomycin, teicoplanin and linezolid were carried 
out on Mueller Hinton agar by the Kirby Bauer disc 
diffusion method. Susceptibilities of the strains to 
daptomycin and tigecycline were performed using 
the E-test (bioMerieux, France) according to the 
recommendations of the CLSI 2011 and the manu-
facturer. The MIC breakpoints used for susceptibility 
for daptomycin and tigecycline were taken as ≤ 4 
μg/ml and ≤0.5 μg/ml, respectively, as approved by 
the FDA.8,13 E. faecalis ATCC 29212 was used as a 
control strain in the study. 
RESULTS
Among 60 enterococcal isolates, 22 (36.7%), 28 
(46.7%), 1 (1.7%) and 9 (15.0%) were isolated in 
2010, 2011, 2012 and 2013, respectively. Thirty 
eight strains (63.0%) were isolated from intensive 
care units and 22 (37%) from internal medicine clin-
ics (Figure 1). All of the strains were resistant to am-
picillin, erythromycin, vancomycin, teicoplanin but 
susceptible to linezolid. Daptomycin MIC values of 
strains were determined between 0.125 and 4 µgr/
ml; all of them were susceptible. MIC50 and MIC90 
values of daptomycin was 1.5 µgr/ml and 2 µgr/ml, 
respectively. Tigecycline MIC values of the strains 
were determined between 0.023 and 0.75  µg/ml; 3 
of the strains having MIC ≥ 0,5 µg/ml were resistant 
to tigecycline. MIC50 and MIC90 values of tigecycline 
were  0.064  µg/ml  and  0.125  µg/ml,  respectively 
(Table 1).
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Table 1. MIC50  and MIC90 (µg/mL) values for daptomycin 
and tigecycline of VRE strains.
MIC (µg/mL)
MIC50 MIC90 MIC Range Susceptibility %
Daptomycin 1,5 2 0,125-3 100%
Tigecycline 0,064 0,125 0,023-0,75 95%
MIC: Minimum inhibitory concentration, VRE: Vancomy-
cin resistant enterococ
DISCUSSION
Vancomycin had been used since 1950s, but the 
emergence of resistance of Enterococcus species 
was not reported until 1988 in the United King-
dom and France. Incremental vancomycin usage 
for MRSA infection may explain the timing.14 Since 
VRE was first isolated in Turkey from nosocomial 
infection in 1998 at Akdeniz University Hospital, the 
incidence of antimicrobial-resistant bacteria has 
continuously increased with the rising consumption 
of antibiotics.15 
Daptomycin, a new lipopeptide antibiotic, is 
highly bactericidal against the majority of gram-pos-
itive human pathogens, including MRSA and VRE. 
Its mechanism of action is unique resulting in the 
destruction of the membrane potential without lysis 
of the cell wall.16 Tigecycline, the first semisynthetic 
glycylcycline available for clinical application, is a 
novel 9-t-butyl-substituted minocycline derivative 
that overcomes several major tetracycline resis-
tance mechanisms. It demonstrates broad-spec-
trum antimicrobial effects against multiple resistant 
gram-positive, gram-negative, anaerobic, and atypi-
cal pathogens.17 Sader et al.18 evaluated the in vi-
tro activity of daptomycin and comparators tested 
against clinical isolates from European hospitals 
over a 7-year period (2003-2009); 7241 consecu-
tive Enterococcus spp. (9.4% VRE) isolates were 
collected in 34 medical centers located in 13 Eu-
ropean countries, Turkey and Israel. All E. faeca-
lis strains were susceptible to daptomycin (MIC50: 
2 µg/ml, MIC90: 2 µg/ml, 100% susceptible). In this 
study, daptomycin and linezolid were the most ac-
tive agents tested against VRE. Aktaş et al.19 eval-
uated the in vitro activity of daptomycin against 118 
VRE strains by broth dilution method and all of the 
strains susceptible to daptomycin (MIC50:1  µg/ml, 
MIC90: 2 µg/ml) and MIC range was 0.125-2 µg/ml. 
At a tertiary care hospital in Turkey, all 31 entero-
coccal strains, 4 of which were VRE, were found to 
be susceptible to daptomycin by E-test method and 
MIC range was 0.094-2 µg/ml.20  In another study in 
a tertiary care hospital in Turkey, all 52 enterococ-
cal strains in which resistance to vancomycin were 
not investigated, were found to be susceptible to 
daptomycin.21 Similar to these results, in our study, 
all of 60 VRE strains were susceptible to daptomy-
cin; MIC50 was 1.5 µg/ml, MIC90 2 µg/ml. Chitnis et 
al.22 evaluated 50 VRE strains, 20 were from clini-
cal samples and 30 were from rectal swabs from 
newborns in Central Indian hospital. All of them 
were susceptible to daptomycin. Among these VRE 
isolates,  MIC  for  daptomycin  was  0.19-1.5  µg/ml 
except two isolates which had MIC of 3 µg/ml. Non-
susceptibility of enterococci to daptomycin (MIC>4 
µg/ml by broth dilution and E-test) remains infre-
quent, with an overall prevalence of 0.6% among 
clinical isolates in a recent series.7 It is declared that 
the resistance of daptomycin in E. faecium is be-
tween 0.5% and 1.5% worldwide.23 Kamboj et al.24 
examined the daptomycin susceptibility profile of all 
isolates collected during episodes of VRE bactere-
mia at a cancer center in New York between 2007-
2009. One hundred seventy six patients had VRE 
bacteremia, including 18 (10.2%) with bacteremia 
due to daptomycin resistant VRE strains; resistance 
rates  were  increased  significantly,  from  3.4%  in 
2007 to 15.2% in 2009. 
Sader et al.25 monitored the in vitro activity of 
tigecycline in 2011 for continued potency worldwide. 
A total of 22.005 gram positive and gram nega-
tive isolates were consecutively collected in North 
America,  Europe,  Latin America  and Asia  Pacific 
Region and tested for susceptibility according to 
the broth microdilution method. Of the VRE isolates 
99% were susceptible to tigecycline. Jones et al.26 
studied resistance patterns of 218 Latin American 
enterococcal isolates. VRE rate was 14% but all 
of them were susceptible to tigecycline and dap-
tomycin. Chen et al.27 evaluated in vitro activity of 
tigecycline to 219 vancomycin resistant E. faecium 
isolates collected during the period from 2006 to 
2010. Among these strains 98.6% were susceptible 
to tigecycline (MIC50: 0.03 µg/ml, MIC90: 0.125 µg/
ml) and MIC range was 0.016-1 µg/ml.  Karaoğlan 
et al.28 monitored in vitro activity of tigecycline in 60 
enterococcal strains from Turkey (57 E. faecium and 
3 E. gallinorum) by E-test method; all of them sus-
ceptible to tigecycline (MIC50: 0.125 µg/ml, MIC90: 
0.5 µg/ml) and MIC range was 0.094-1 µg/ml. Of 
our 60 VRE isolates, three of them (5%) were resis-
tant to tigecycline. Our resistant rate to tigecycline 
was higher than the other studies. The limitatiton of 
our study is that the subtyping was not performed. 
It would be better if we could have identified E. spe-Altun S, et al. Daptomycin and tigecycline susceptibility of VRE strains 110
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cies as E. faecium or E. faecalis. It is known that E. 
faecium isolates are more resistant than E. faecalis 
isolates.4 
Conclusion
As a conclusion; all of the strains were susceptible to 
daptomycin, so this agent can be used at the treat-
ment of VRE. Resistance to tigecycline was exhib-
ited by 5% of VRE isolates. We think that clinicians 
should be aware of the possibility of the emergence 
of tigecycline nonsusceptibility and should closely 
monitor tigecycline MICs of enterococcal strains.
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